เอกสารอ้างอิง
1.Martín Arias LH, Martín González A, Sanz Fadrique R, Vazquez ES. Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies. J Clin Pharmacol. 2019.
2.Varga Z, Sabzwari SRA, Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus. 2017;9(4):e1144. Published 2017.
3.Grosser, Tilo, et al “Pharmacotherapy of inflammation, Fever, Pain, and Gout” Googman&Gilman’s.The pharmacological basis of therapeutics, 13rd editions.Laurence L.Brunton et al.McGraw-Hill, 2017.
4.Drugs|AccessMedicine|McGraw-Hill Medical [Internet].[cited 2020 Jul 10].Available from:https://accessmedicine.mhmedical.com/drugs.aspx?gbosID=423475#monoNumber=423475§ionID=243290283&tab=tab0.
5.Schmidt M, Sørensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ [Internet]. 2018 Sep 4 [cited 2020 Jul 8];362. Available from: https://www.bmj.com/content/362/bmj วันที่ตอบ : 01 ธ.ค. 63 - 10:47:34